CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...